Global /United States /Healthcare /Medical Devices /HAE
chevron_leftBack
Haemonetics Corp. logo

Haemonetics Corp.

HAE
NYSE: HAE Delayed
59.01USD -1.4%
As of 14 June 2026, Haemonetics Corp. has a market cap of $2.74B USD, ranking #5779 globally and #1512 in the United States. It ranks #454 in the Healthcare sector, and #96 in the Medical Devices industry.
Global Rank
5779
Country Rank
1512
Sector Rank
454
Industry Rank
96
Key Stats
Market Cap
$2.74BUSD
Enterprise Value
$3.58BUSD
Revenue (TTM)
$1.32BUSD
EBITDA (TTM)
$364.9MUSD
Net Income (TTM)
$175.44MUSD
EBITDA Margin
28%
Profit Margin
13%
PE Ratio
16.2
Forward PE
11.4
PS Ratio
2.1
PB Ratio
3.1
EV/EBITDA
9.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Christopher Simon open_in_new
Employees
3,023
Founded
1971
IPO
09 May 1991
Website
haemonetics.com open_in_new
1d 1w 1m 3m 6m 1y
-1.4% -3.5% 9.2% -11% 17% -5.8%

News

Loading...

HAE Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NYSE
MIC: XNYS
PRIMARY
HAE
Haemonetics Corp
ISIN: US4050241003
Shares Out.:
45.446M1 Shares Float: 44.589M2
TV:
SA:
YF:
HAE
GF:
NQ:
HAE
BA:
HAE
MS:
59.01 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Haemonetics Corp.

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Similar Companies

Industry: Medical Devices (United States)
Name
Market Cap diff.
PE
$173.27B
6K%
25.8
$160.73B
6K%
56.7
$159.07B
6K%
25.6
DHR
$126.55B
5K%
34.7
SYK
$120.69B
4K%
38.3
$84.93B
3K%
24.5
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
MDT
$101.9B
4K%
22.2
$97.46B
84.32B EUR
3K%
36.7
7741
$61.41B
9.83T JPY
2K%
40.0
$45.47B
39.34B EUR
2K%
18.7
ALC
$36.38B
28.99B CHF
1K%
37.9
$30.06B
203.66B CNY
996%
26.0
chevron_leftBack